Most gut peptide research has been conducted in rodent models, and while the mechanistic data is compelling, translation to human outcomes has not been established through large clinical trials
Products may carry risks, including immunogenicity or impurities, if mishandled
A small clinical trial confirmed these findings, showing that exenatide, another GLP-1 agonist, significantly reduced intracranial pressure in patients with idiopathic intracranial hypertension, greatly improving headache symptoms
And yet another study found that acetyl L-carnitine can support brain health and help maintain normal activity levels as age increases, without affecting body weight
2022;71: Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide Altimmune